209 related articles for article (PubMed ID: 28397426)
1. Study of CD69 antigen expression and integrity of leukocyte cellular membrane in stored platelet concentrates following irradiation and treatment with Mirasol® PRT System.
Lachert E; Woźniak J; Antoniewicz-Papis J; Krzywdzińska A; Kubis J; Mikołowska A; Letowska M
Adv Clin Exp Med; 2017; 26(1):7-13. PubMed ID: 28397426
[TBL] [Abstract][Full Text] [Related]
2. Quality control of riboflavin-treated platelet concentrates using Mirasol® PRT system: Polish experience.
Lachert E; Kubis J; Antoniewicz-Papis J; Rosiek A; Woźniak J; Piotrowski D; Przybylska Z; Mikołowska A; Marschner S; Łętowska M
Adv Clin Exp Med; 2018 Jun; 27(6):765-772. PubMed ID: 29877637
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
[TBL] [Abstract][Full Text] [Related]
4. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/- double knockout mice.
Fast LD; DiLeone G; Cardarelli G; Li J; Goodrich R
Transfusion; 2006 Sep; 46(9):1553-60. PubMed ID: 16965583
[TBL] [Abstract][Full Text] [Related]
5. Riboflavin and ultraviolet light for pathogen reduction of murine cytomegalovirus in blood products.
Keil SD; Saakadze N; Bowen R; Newman JL; Karatela S; Gordy P; Marschner S; Roback J; Hillyer CD
Transfusion; 2015 Apr; 55(4):858-63. PubMed ID: 25438832
[TBL] [Abstract][Full Text] [Related]
6. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro.
Zeddies S; De Cuyper IM; van der Meer PF; Daal BB; de Korte D; Gutiérrez L; Thijssen-Timmer DC
Transfusion; 2014 Sep; 54(9):2292-300. PubMed ID: 24689812
[TBL] [Abstract][Full Text] [Related]
7. Mirasol PRT system inactivation efficacy evaluated in platelet concentrates by bacteria-contamination model.
Jocić M; Trkuljić M; Jovicić D; Borovcanin N; Todorović M; Balint B
Vojnosanit Pregl; 2011 Dec; 68(12):1041-6. PubMed ID: 22352265
[TBL] [Abstract][Full Text] [Related]
8. Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution.
Ignatova AA; Karpova OV; Trakhtman PE; Rumiantsev SA; Panteleev MA
Vox Sang; 2016 Apr; 110(3):244-52. PubMed ID: 26646605
[TBL] [Abstract][Full Text] [Related]
9. White blood cell inactivation after treatment with riboflavin and ultraviolet light.
Marschner S; Fast LD; Baldwin WM; Slichter SJ; Goodrich RP
Transfusion; 2010 Nov; 50(11):2489-98. PubMed ID: 20529002
[TBL] [Abstract][Full Text] [Related]
10. Hemovigilance survey of pathogen-reduced blood components in the Warsaw Region in the 2009 to 2013 period.
Łętowska M; Przybylska Z; Piotrowski D; Lachert E; Rosiek A; Rzymkiewicz L; Cardoso M
Transfusion; 2016 Mar; 56 Suppl 1():S39-44. PubMed ID: 27001360
[TBL] [Abstract][Full Text] [Related]
11. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.
Picker SM; Steisel A; Gathof BS
Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255
[TBL] [Abstract][Full Text] [Related]
12. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study.
Picker SM; Steisel A; Gathof BS
Transfus Apher Sci; 2009 Apr; 40(2):79-85. PubMed ID: 19233725
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive proteomics study on platelet concentrates: Platelet proteome, storage time and Mirasol pathogen reduction technology.
Salunkhe V; De Cuyper IM; Papadopoulos P; van der Meer PF; Daal BB; Villa-Fajardo M; de Korte D; van den Berg TK; Gutiérrez L
Platelets; 2019; 30(3):368-379. PubMed ID: 29553857
[TBL] [Abstract][Full Text] [Related]
14. Real-time measurement of platelet shape change by light scattering under riboflavin and ultraviolet light treatment.
Terada C; Shiba M; Satake M; Tadokoro K
Transfusion; 2016 Mar; 56(3):587-95. PubMed ID: 26536611
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation.
Fast LD; DiLeone G; Marschner S
Transfusion; 2011 Jul; 51(7):1397-404. PubMed ID: 21155832
[TBL] [Abstract][Full Text] [Related]
16. [Effects of use of riboflavin and ultraviolet light for pathogen inactivation on quality of platelet concentrates].
Stanojković Z; Antić A; Stojanović M
Vojnosanit Pregl; 2011 Jun; 68(6):489-94. PubMed ID: 21818915
[TBL] [Abstract][Full Text] [Related]
17. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction.
Tauszig ME; Picker SM; Gathof BS
Transfus Apher Sci; 2012 Feb; 46(1):33-7. PubMed ID: 22119364
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology.
Li J; Lockerbie O; de Korte D; Rice J; McLean R; Goodrich RP
Transfusion; 2005 Jun; 45(6):920-6. PubMed ID: 15934990
[TBL] [Abstract][Full Text] [Related]
19. Haemostatic profile of riboflavin-treated apheresis platelet concentrates.
Petrou E; Nikolopoulos GK; Kriebardis AG; Pantavou K; Loukopoulou E; Tsantes AG; Georgatzakou HT; Maratou E; Rapti E; Mellou S; Kokoris S; Gialeraki A; Tsantes AE
Blood Transfus; 2022 May; 20(3):223-234. PubMed ID: 34059193
[TBL] [Abstract][Full Text] [Related]
20. Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets.
Mastroianni MA; Llohn AH; Akkök ÇA; Skogheim R; Ødegaard ER; Nybruket MJ; Flesland A; Mousavi SA
Transfus Apher Sci; 2013 Oct; 49(2):285-90. PubMed ID: 23820429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
